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Abstract
The Epic Platform was developed for the unbiased detec‐
tion and molecular characterization of circulating tumour
cells (CTCs). Here, we report assay performance data,
including accuracy, linearity, specificity and intra/inter-
assay precision of CTC enumeration in healthy donor (HD)
blood samples spiked with varying concentrations of
cancer cell line controls (CLCs). Additionally, we demon‐
strate clinical feasibility for CTC detection in a small cohort
of metastatic castrate-resistant prostate cancer (mCRPC)
patients. The Epic Platform demonstrated accuracy,
linearity and sensitivity for the enumeration of all CLC
concentrations tested. Furthermore, we established the
precision between multiple operators and slide staining
batches and assay specificity showing zero CTCs detected
in 18 healthy donor samples. In a clinical feasibility study,
at least one traditional CTC/mL (CK+, CD45-, and intact
nuclei) was detected in 89 % of 44 mCRPC samples,
whereas 100 % of samples had CTCs enumerated if
additional CTC subpopulations (CK-/CD45- and CK+
apoptotic CTCs) were included in the analysis. In addition
to presenting Epic Platform’s performance with respect to
CTC enumeration, we provide examples of its integrated
downstream capabilities, including protein biomarker
expression and downstream genomic analyses at single cell
resolution.
Keywords Analytical Validation, Biomarker, Circulating
Tumour Cells, CTC, CTM, Clinical Feasibility, Epic CTC
Platform, Fluid Biopsy, Liquid Biopsy, Metastasis
1. Introduction
Over 90 % of cancer-related deaths from solid tumours are
caused by complications of tumour metastasis [1]: the
translocation of primary tumour cells to a distant tissue,
followed by adaptation to and colonization of the micro‐
environment of a secondary site to facilitate tumour cell
proliferation and the macroscopic formation of metastatic
lesions [2, 3]. Circulating tumour cells (CTCs) are thought
to represent the haematologic phase of tumour metastasis,
1J Circ Biomark, 2015, 4:3 | doi: 10.5772/60725
as CTC detection and enumeration are greater in metastatic
patients than those with high-risk or benign disease [4, 5].
CTCs were first discovered in the late 1800s [5, 6] and exist
in frequencies in the range of one in one billion blood cells
[2, 5]. Despite their rare nature, monitoring disease by the
detection of CTCs has several key advantages over solid
tissue biopsies [7]. CTCs are accessible via peripheral
venous phlebotomy, which is less invasive to patients than
solid tissue biopsies. In addition, some solid tissue biopsies
require expensive radiographic imaging to guide biopsy
needles, and can be potentially hazardous to patients who
may already be weakened by current or previous history
of cancer treatment. Importantly, there can also be signifi‐
cant intra-patient tumour evolution over time [8-11], for
which blood collection can represent a real-time fluid
biopsy, and is more amenable for repeat sampling than
tissue biopsies.
The enumeration of CTCs has clinically validated prognos‐
tic value to predict progression free survival (PFS) and
overall survival (OS) in metastatic breast cancer [12],
prostate cancer [13] and colorectal carcinoma [14] patients
using the CellSearch platform. Beyond enumeration, the
molecular characterization of CTCs has potential to predict
response to therapy [4, 15]. The integration of CTC enu‐
meration and biomarker expression analysis has been
proposed for use in early clinical development of thera‐
peutics, as intermediate endpoints in clinical trials, and in
stratification of patients for targeted therapy [16, 17].
CTC  heterogeneity  has  been  observed  both  within
individual  patients  and  across  cohorts  of  patients,
displaying a range of gene or protein expression signa‐
tures  [4],  cell  size  [18,  19],  and  cell  density  [9].  This
fundamental  inter-  and  intra-patient  heterogeneity  has
made it challenging to define a standard CTC definition
and  reference  range  for  the  development  of  CTC
detection  platforms.  Due  to  the  rare  nature  of  CTCs,
several  CTC  detection  and  characterization  methods
utilize  enrichment  strategies  to  isolate  CTCs  from
peripheral  blood cells.  Such enrichment techniques rely
on  CTC  expression  of  epithelial  markers  (EpCAM,
cytokeratin),  depletion  of  cells  expressing  a  common
leukocyte marker (CD45), selection of cells with specific
physical  properties  (cell  size,  density,  deformity),  or  a
combination of  epitope and physical  property selection
[16, 17].
Positive selection of CTCs is the most common mechanism
of CTC enrichment and is utilized by many technologies in
development, including CellSearch, the only platform
currently FDA-cleared for prognostic applications [5, 16].
However, emerging literature suggests that CTCs display
degrees of epithelial epitope plasticity, and have been
reported to have more than 10 times less EpCAM expres‐
sion per cell than solid primary and metastatic tissue
samples [20]. Additionally, common epithelial cell surface
markers (EpCAM, E-Cadherin, cytokeratins) are often
downregulated or absent in pluripotent cancer stem cells
or cells undergoing epithelial-to-mesenchymal transition
(EMT) [21, 22]. In preclinical models, cells undergoing de-
differentiation or EMT have been associated with increased
motility, invasiveness and tumour aggressiveness [23-25].
Thus, detection strategies that rely on epithelial marker
enrichment might miss biologically relevant CTC subpo‐
pulations and hinder comprehensive analysis of CTC
heterogeneity. To address this issue, some CTC detection
platforms integrate negative selection, the depletion of
CD45(+) cells from whole blood, as a method to enrich
CTCs in an effort to detect epithelial marker-negative cells,
and studies characterizing this strategy are ongoing [26-28].
Alternatively, size exclusion methods select for cells that
are larger than white blood cells and are not biased by cell
surface marker expression [16, 29-31]. However, studies of
prostate cancer, breast cancer, and melanoma CTCs have
found considerable overlap between the lower limit of CTC
diameter and median white blood cell diameter [18, 26, 32],
which impacts the ability of size exclusion methods to
detect small CTCs. Size exclusion and micro-filtration
systems can also reduce high CTC recovery due to cell
membrane stress, thus reducing dynamic range and cell
viability during the cell capture process [33], and some
membrane filtration systems have been reported to show
CTC capture variability, as well as frequent sample
clogging on filters [34].
Many emerging CTC detection modalities make use of
microfluidics to select via size and deformity [35], aid
enrichment by increasing epitope availability [32, 36, 37],
or assist in immunomagnetic positive or negative epitope
selection [26]. Analogous to size exclusion and epitope
selection, microfluidic techniques must utilize assump‐
tions about the physical nature of CTCs they are engineered
to detect. Without an established reference range or
universal definition of CTC, any chosen parameters of CTC
enrichment might bias sampling and miss biologically
relevant CTCs. While microfluidic devices have displayed
improved sensitivity of CTC detection and higher separa‐
tion efficiency compared to first-generation approaches
[33, 38], one drawback is the potential for clogging [38, 39],
which has important implications for accurate CTC
enumeration for patients with high CTC burden, or for the
detection of CTC clusters. Additional drawbacks can
include low sample throughput due to the complex
integration of external electrical/magnetic fields, and
prolonged processing time due to the device’s high fluidic
resistance [34, 39]. Additionally, CTC isolation using
microfluidic chips typically requires a fresh blood sample
to be processed within hours of patient blood draw at the
clinical site, rather than allowing for shipment and blood
sample processing at a centralized CLIA laboratory [26].
Importantly, processing an entire fresh blood sample
through a microfluidic chip may preclude the ability to
store morphologically intact CTCs in a biorepository for
retrospective biomarker analyses.
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To overcome the challenges outlined above, we developed
an unbiased method to detect and characterize CTCs
without cell enrichment, depletion or microfluidic manip‐
ulation, and with the added feature of being able to store
samples in a central biorepository. While detection of CTCs
has prognostic value for patient survival [5, 12-14], it is a
comprehensive portrait of biomarker expression, hetero‐
geneity and clonal evolution that has been proposed as
having great promise to derive clinically actionable CTC
signatures for drug development, patient stratification and
evaluation of drug resistance mechanisms [16, 17, 40]. To
this end, the Epic CTC Platform was designed with
integrated downstream capabilities for the evaluation of
protein (immunofluorescence) and genetic (FISH, NGS)
biomarkers with single cell resolution.
The following report describes the analytical performance
of the Epic CTC Platform, clinical feasibility for the detec‐
tion of both traditional and non-traditional CTCs in
mCRPC patients, and a description of the platform’s
downstream biomarker analytic capabilities.
2. Methods
2.1 Sample Receipt, Processing and CTC Enumeration
Samples were processed and analysed using the Epic CTC
platform  (Figure  1)  as  previously  described  [41-43].
Briefly, blood samples were collected in 10 mL cell-free
preservative blood tubes (Streck, Omaha, Nebraska) and
shipped to Epic Sciences. Red blood cell (RBC) lysis was
performed using  ammonium chloride  solution.  Follow‐
ing centrifugation, all nucleated cells were deposited on
up to 12 glass slides per sample at a concentration of 3 x
106  cells/slide and frozen at  -80 ºC until  analysis.  After
thawing, two slides per sample were immunofluorescent‐
ly  (IF)  stained  with  a  cocktail  of  antibodies  targeting
cytokeratins (CK), CD45, and 4’,6-Diamidino-2-phenylin‐
dole,  dihydrochloride  (DAPI).  Slides  were  scanned  by
Epic’s  rapid  fluorescent  scanning  method  [43],  which
analyses each nucleated cell  per slide using a propriet‐
ary algorithm developed within the context of haemato‐
pathology standards.  In short,  the algorithm utilizes 90
cellular parameters, including marker expression and cell
morphology,  to  differentiate  candidate  CTCs  from
surrounding  white  blood  cells  (WBCs)  [43].  Candidate
CTCs  were  identified  and  displayed  in  a  web-based
report,  and  trained  technicians  confirmed  CTC  candi‐
dates  as  being  classified  into  one  of  the  following
categories (Figure 2):
Traditional CTCs (Figure 2A): defined as cells CK(+),
CD45(-), intact DAPI, and are generally larger and mor‐
phologically distinct from surrounding WBCs.
Small CTCs (Figure 2B): defined as CK(+), CD45(-), intact
DAPI cells that are the same size or smaller than the size of
neighbouring WBCs.
Figure 1. Epic Platform workflow for sample preparation, CTC enumeration and biomarker analysis. Upon patient blood sample receipt at Epic Sciences,
1) whole blood is lysed and nucleated cells (3 x 106 per slide) are deposited onto 10-12 microscope slides and are frozen at -80 ºC until analysis. 2) Two slides
per patient sample are thawed and stained with a cocktail of antibodies including cytokeratin, CD45, DAPI to perform CTC enumeration, and a fourth
fluorescent channel is available for the evaluation of protein biomarker expression. 3) Stained slides are scanned and 4) the resulting images are analysed
using a multi-parametric digital pathology algorithm to detect CTC candidates and quantitate biomarker expression levels. CTC classifications are displayed
in a web-based report and are confirmed by trained technicians. 5) CTC enumeration and biomarker expression results are compiled and reported.
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CTC Clusters (Figure 2C): defined as two or more adjacent
CTCs, containing at least one traditional CTC, with shared
cytoplasmic boundaries.
CK(-) CTCs (Figure 2D): defined as CK(-), CD45(-), with
DAPI intact.
Apoptotic CTCs (Figure 2E): defined as CK(+), CD45(-)
with a DAPI pattern of chromosomal condensation and/or
nuclear fragmentation/blebbing that is consistent with the
classic definition of apoptosis [44].
Figure 2. Representative CTC subtypes detected by the Epic Platform.
CTCs from prostate cancer patient samples were enumerated using the Epic
Platform. Representative 10X immunofluorescence images for the DAPI
(blue), cytokeratin (red), CD45 (green) channels are shown for CTC subtypes
and the surrounding white blood cells (WBCs), with the three-channel
merge to the far left of each image. Classified CTC subtypes include A)
Traditional CTCs (CK+, CD45-, DAPI+/intact), B) Small CTCs (CK+, CD45-,
DAPI+/intact, with similar nuclear size to that of the surrounding WBCs),
C) CTC clusters (two or more adjacent traditional CTCs that share
cytoplasmic boundaries), D) CK- CTCs (CK-, CD45-, DAPI+/intact), and E)
Apoptotic CTCs (CK+, CD45-, with DAPI staining pattern consistent with
chromosomal condensation and/or nuclear fragmentation).
2.2 Analytical Validation of CTC Detection
Cultured cancer cell line cells (CLCs; COLO-205) were
spiked into whole blood specimens from healthy donors
(HD) at varying concentrations ranging from six-300 CLCs/
slide (six slides each of six, 12, 25, 50, 100, 300 CLCs/slide,
and 24 additional slides were created for the 25 and 300
CLCs/slide dilution). Additionally, five slides of unspiked
HD samples were prepared. All blood samples (spiked or
unspiked) were processed as described above, and 3 x 106
nucleated cells were deposited per slide. Slides were
stained using the Epic standard three-colour assay (CK/
CD45/DAPI), and scanned using the Epic CTC platform.
One assay (staining/scanning) run consisted of three
replicate tests of two slides per test (six slides total).
Following scanning and CTC classification, the number of
CLCs enumerated on two replicate slides was converted to
CLCs per millilitre of blood, and the resulting values were
used to assess four critical assay performance characteris‐
tics (Figure 3A):




Cell deposition repeatability and assay accuracy were
evaluated by measuring the DAPI counts per slide and
calculating percent nucleated cell recovery for three
replicate tests (two slides per test; six slides total) for each
of six serial CLC dilutions (six, 12, 25, 50, 100 and 300 CLCs/
slide), and for five slides of unspiked healthy donor (HD)
blood (zero CLCs/slide). Percent coefficient of variation
(%CV) of DAPI counts was calculated for each CLC
dilution tested.
Assay linearity was evaluated by plotting the actual CLCs/
slide recovered versus the theoretical number of CLCs/
slide for each of the CLC concentrations tested, where each
concentration was tested in triplicate tests (two slides per
test). The linear regression was calculated. Assay specificity
was determined by measuring the number of CLCs
detected on the five unspiked healthy donor slides (zero
CLCs/mL), as well as in 18 healthy donor samples (two
slides tested per sample) in a clinical feasibility analysis
(Figure 4).
Assay precision/repeatability was measured by calculating
the percent coefficient of variation (%CV) of CLC counts
from the 25 CLCs/slide and 300 CLCs/slide dilutions. Intra-
assay variability was measured for one operator who
performed three tests on one day (two replicate slides/test;
six slides total), whereas inter-assay variability was
measured across three operators who performed five assay
runs total (one run per day), with each run consisting of
three tests of two slides per test (30 slides total). Intra-
operator repeatability was measured for one operator who
performed three assay runs (one run per day), with each
run consisting of three replicate tests of two slides/test (18
slides total). Inter-operator repeatability was measured for
three operators who performed one assay run each (18
slides total).
2.3 Clinical Feasibility of CTC Detection
Forty-four (44) blood samples from all-comer metastatic
castrate-resistant prostate cancer (mCRPC) patients were
sent to Epic Sciences, processed onto slides, and two slides
per sample were tested for CTC enumeration as described
above. CTC enumeration (CTC/mL) was compared to that
found for 18 healthy donor blood samples (two slides tested
per sample), which also further addressed assay specificity.
The prevalence of CTC clusters, CK- CTCs and apoptotic
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CTCs are also reported for the mCRPC cohort as percent of
samples containing each subtype.
3. Results
3.1 Analytical Validation
To assess assay accuracy, linearity, specificity and preci‐
sion/repeatability, the CK(+), CD45(-), DAPI(+) COLO-205
cancer cell line control (CLC) was spiked into healthy donor
blood and processed onto slides as mock clinical samples.
Six (6) slides each of six CLC dilutions (six, 12, 25, 50, 100,
300 CLCs/3 x 106 WBCs per slide and 24 additional slides
for both the 25 and 300 CLCs/slide dilution) were prepared,
as well as five slides of unspiked HD samples. A descrip‐
tion of the assay performance characteristics evaluated is
described in Figure 3A.
3.1.1 Cell Deposition Repeatability, Assay Accuracy and
Linearity
To evaluate the repeatability of the cell deposition onto
slides, one operator performed three replicate CTC enu‐
meration tests (two slides/test; six slides total) for each of
the six CLC dilutions, as well as for five replicate unspiked
HD slides, for a total of 41 slides. The numbers of nucleated
cells per slide (DAPI counts) were counted, and the percent
recovery of nucleated cells per CLC dilution was calculated
(Figure 3B). Across 41 slides, the mean percent recovery
was 88 % (2.64x106 nucleated cells/slide), with an observed
coefficient of variation (%CV) of 9.7 %. The %CVs for each
cell dilution were 6.7 % (zero CLCs/slide), 6.3 % (six CLCs/
slide), 3.0 % (12 CLCs/slide), 7.0 % (25 CLCs/slide), 2.7 %
(50 CLCs/slide), 3.8 % (100 CLCs/slide), and 1.2 % (300
CLCs/slide). Assay linearity was evaluated by plotting the
number of CLCs recovered per slide for each of the spike-
in concentrations from three replicate tests (two slides/test;
six slides total) against the calculated CLC spike-in con‐
centration (Figure 3C), and the linear regression was
calculated. The assay was shown to be linear across all
sample dilutions tested (r2=0.999). Importantly, zero CTCs
were enumerated in the unspiked healthy donor slides,
thereby showing assay specificity. Assay specificity is
further established in the clinical feasibility testing of 18
healthy donor samples (two slides per sample tested), as
shown in Figure 4.
Figure 3. Analytical Validation of the Epic Platform. A) The analytical characteristics assessed to benchmark the performance of the Epic CTC platform.
Varying concentrations of COLO-205 cell line cells (CLCs) were spiked into healthy donor blood, red blood cells lysed, and 3 x 106 nucleated cells were
deposited onto slides, ranging from 0-300 CLCs/slide. Slides were stained with a cocktail of CK, CD45 and DAPI antibodies, and assay accuracy, linearity,
specificity and precision were determined as described in the methods. For each analysis, a “run” is comprised of three tests, with each test consisting of two
replicate slides. B) The accuracy and repeatability of cell deposition was assessed calculating percent nucleated cell recovery (y-axis; Mean ± SEM) for one run
each of six serial CLC dilutions (six, 12, 25, 50, 100 and 300 CLCs/slide), and for five slides of unspiked healthy donor (HD) blood (zero CLCs/slide). C) Assay
linearity was characterized by plotting the actual CLCs/slide recovered (y-axis) versus the theoretical number of CLCs/slide (x-axis) for seven CLC concen‐
trations (six slides tested/concentration), and the linear regression was calculated. Assay specificity was determined by measuring the number of CLCs detected
on the unspiked healthy donor slides (zero CLCs/mL). D) Assay precision/repeatability was measured by calculating the percent coefficient of variation (%CV)
for CLC counts from the 25 CLCs/slide and 300 CLCs/slide dilutions. Intra-assay variability was measured for one operator who performed one assay run,
whereas inter-assay variability was measured across three operators who performed five assay runs total (one assay run per day). Intra-operator repeatability
was measured for one operator who performed three assay runs on separate days, whereas inter-operator repeatability was measured for thee operators who
performed one assay run each.
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Figure 4. Clinical feasibility of CTC enumeration in metastatic castrate-
resistant prostate cancer patient samples. Forty-four (44) mCRPC patient
blood samples were tested for CTC enumeration using the Epic Platform,
and the results were compared to those from 18 healthy donor (HD) blood
samples. A) CTC incidence was calculated as CTC per millilitre (CTC/mL)
of patient blood for traditional CTCs and CTC clusters (left, CTCs + clusters)
and all CTC candidates (right; CTCs, CTC clusters, CK- CTCs, and apoptotic
CTCs). Each dot on the graph is representative of the CTC/mL value for that
patient sample. B) Summary of the range, median and mean CTC/mL values
for 18 healthy donor and 44 mCRPC samples for traditional CTCs and CTC
clusters (left) and all CTC candidates (right).
3.1.2 Assay Precision and Repeatability
Precision of the Epic Platform was assessed intra- and inter-
assay as well as intra- and inter-operator by calculating the
observed variation in the enumeration of CLCs in the 25
CLCs/slide and 300 CLCs/slide dilutions (Figure 3D). One
assay run consisted of three replicate tests, with two slides
stained per test (six slides total) per CLC concentration.
Intra-assay repeatability was assessed by calculating the
%CV of CLCs detected per millilitre (CLCs/mL) of blood
from slides prepared by a single operator who performed
one assay run (six slides total) for both the 25 CLCs/slide
and 300 CLCs/slide dilutions. The observed %CVs were
calculated to be 20.7 % and 1.3 %, respectively. Inter-assay
repeatability was determined from calculating the %CV of
CLCs/mL blood detected based upon five assay runs
performed by three operators on separate days, for a total
of 30 slides evaluated per CLC dilution. The resulting
%CVs calculated were 4.7 % for 300 CLCs/slide, and 17.3 %
for 25 CLCs/slide. Intra-operator precision was evaluated
for one operator who performed one assay run on three
separate days (18 slides total), which resulted in %CVs of
3.1 % for 300 CLCs/slide and 20.9 % for 25 CLCs/slide.
Finally, inter-operator precision was assessed for three
operators who performed one assay run each (18 slides
total) on separate days. For this parameter, the observed
%CV for the 300 CLCs/slide dilution was found to be 5.3 %
and 16.5 % for the 25 CLCs/slide dilution.
Coefficient of variation for the detection of 300 CLCs/slide
increased from 1.3 % for samples analysed by a single
operator in a single run to only 3.1 % when the single
operator performed a single run on three separate days,
whereas it increased to only 4.7 % when three operators
performed five runs in total over five days. For the 25 CLCs/
slide dilution, the %CV in CLC detection was the same if
an operator performed a single run on one day, or if he
performed one run on three separate days (20.7 % and 20.9
%, respectively). Similarly, the %CV in detection of 25
CLCs/slide was found to be similar between a single
operator who performed one run and multiple operators
who performed runs on separate days. The variability for
the detection of 25 CLCs/slide was found overall to be
higher than that for 300 CLCs/slide, which is not unexpect‐
ed due to the inherent variability of performing serial cell
dilutions, and the %CV was found to be at or under 20 %
for all parameters tested.
3.2 Clinical Feasibility
To establish clinical feasibility, we tested 44 all-comer
metastatic castrate-resistant prostate cancer (mCRPC)
samples, and compared CTC enumeration to that from 18
healthy donor samples (Figure 4). Traditional CTCs (CK+/
CD45-/intact nuclei) and clusters of traditional CTCs were
detected in 89 % of the mCRPC samples analysed with a
range of 0-20 CTC/mL (median=2.0 CTC/mL), whereas 23
% of samples were found to have CTC clusters. Considering
all possible CTC candidates (including non-traditional
CK(-) CTCs and apoptotic CTCs), 100 % of the mCRPC
samples had detectable CTCs (Figure 4B) with a range of
1-28 CTC/mL (median=6.0 CTC/mL). In this cohort, we
observed that 70 % of samples had CK(-) CTCs, whereas 77
% had apoptotic CTCs. In contrast, zero CTCs were
enumerated in the 18 healthy donor samples tested, which
further exhibits the specificity of the Epic Platform. So far,
CTC and biomarker stability on patient slides have been
demonstrated for up to one year, with studies ongoing to
determine longer term storage stability (data not shown).
3.3 Downstream Capabilities of the Epic Platform
In addition to CTC enumeration, the Epic CTC Platform
was designed with integrated downstream capabilities for
the evaluation of cell morphology characteristics, protein
biomarker expression and genomic analyses (FISH and
NGS). The platform has an open fourth fluorescent channel
for the evaluation of protein biomarker expression in
patient CTCs (Figure 1, Step 2 of the CTC Assay workflow),
with a fifth channel currently in development. Currently, a
wide variety of fourth channel markers have been devel‐
oped targeting multiple disease indications, EMT cell
markers and drug sensitivities. Using the Epic Platform, it
is possible to simultaneously evaluate the expression of
targetable protein biomarkers (IF), the presence of specific
driver genomic alterations (FISH) and genome-wide copy
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number alterations (NGS) from a single tube of blood, and
importantly, within individual patient CTCs. Both FISH
and NGS analysis can be performed on single CTCs
detected using the immunofluorescence assay workflow
(Figure 1). The potential to integrate the analysis of multiple
biomarkers from a single patient blood sample, including
genomic, protein and morphological endpoints, holds
great promise for better understanding of disease progres‐
sion, heterogeneity and sensitivity/resistance to targeted
therapies [16, 40, 45].
As proof of concept (Figure 5), slides were created from
healthy donor blood samples spiked with prostate cancer
cell lines (VCaP, LnCaP and PC3), and were analysed to
confirm the presence of known protein and genetic markers
associated with prostate cancer disease progression and/or
resistance to targeted therapies. Common molecular
alterations in mCRPC include changes in androgen
receptor (AR) signalling through alterations in AR protein
expression levels and gene copy number variations, the
presence of AR splice variants and mutations, and altered
PI3K-axis signalling through PTEN gene deletions 46-49].
Relative AR protein expression was analysed in VCaP,
LnCaP and PC3 CLCs detected using the fourth channel
capability of the Epic Platform (Figure 5A), and confirmed
with the relative AR expression known to be found in the
high-, medium- and low-AR expressing cell lines, respec‐
tively. PTEN tumour suppressor gene loss was evaluated
in these prostate cancer CLCs by FISH (Figure 5B), where
the signals for PTEN (green) and CEP10 (red) can be
compared between the CLC (yellow circle) and the sur‐
rounding white blood cells (white carrots). In all three CLC
examples, the CEP10 signals were found to be greater than
two, which is indicative of polyploidy and is consistent
with the tumour origin of the CLCs. The VCaP CLC was
shown to have PTEN non-deleted status (PTEN=CEP10;
three signals each), whereas LnCaP showed heterozygous
PTEN loss (PTEN=2; CEP10=4) and PC3 showed homozy‐
gous PTEN loss (PTEN=0, CEP10=4). The presence of
surrounding WBCs provide ample controls for evaluating
the false-positive rate of detection of genetic alterations.
Additionally, AR gene copy number variation (CNV) was
evaluated in single CLCs using next-generation sequencing
(NGS; Figure 5C). As reported previously, AR gene
amplification was found in the VCaP CLC [50, 51], but not
the LnCaP or PC3 CLCs. Using the platform’s integrated
downstream analysis, multiplexed evaluation of genomic
Figure 5. Epic Platform capabilities for the evaluation of protein and genetic biomarkers. Human prostate cancer cell line control cells (CLCs; VCaP, LnCaP
or PC3) were spiked into healthy donor blood, processed onto slides and stained with CK, CD45, DAPI and N-terminal androgen receptor (AR) antibodies.
Additional slides were processed for PTEN loss by FISH. Subsequently, individual CLCs were recovered and analysed for whole genome copy number
variation by NGS. A) Representative images (10X) of individual CLCs detected, each with varying levels of AR expression (AR signal denoted in white). B)
Representative images of PTEN gene deletion status in CLCs (yellow circles) and surrounding WBCs (white carrots), as determined by PTEN FISH analysis.
Blue: DAPI, Red: CEP10 signals, Green: PTEN signals. The number of PTEN and CEP10 signals found in each CLC example are reported to the right of the
image. C) Comparison of log2 CNV (y-axis) found within isolated VCaP (red), PC3 (grey), and LnCaP (blue) CLCs across the X chromosome (x-axis). Each
data point represents the relative copy number within a 100,000 bp window normalized to healthy donor control WBC CNV. The highlighted window (yellow
dotted line) contains the AR gene.
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and protein biomarkers within a patient sample and
individual patient CTCs offers a unique opportunity to
better understand mechanisms of resistance to therapy and
to inform the optimization of targeted therapy regimens.
As recently summarized by Macaulay and Voet, substantial
advances in single cell genomic analyses for the detection
of point mutations, copy number variation (CNV), loss of
heterozygosity (LOH) and structural variants have been
made [52]. However, amplifying DNA material via whole
genome amplification (WGA) has the inherent risk of
creating bias and false-positive/negative results. An
alternative strategy to increase DNA quantity while
preventing the complications associated with single cell
analysis, would be to pool individual CTCs isolated from
a patient sample by phenotypic subtype. However, this
would negatively impact the ability to evaluate intra-
patient heterogeneity. Development of quality control (QC)
criteria for evaluating the quality of both the NGS library
and post-sequencing data has been described and imple‐
mented to avoid such false-positive and false-negative
results [53]. Additionally, secondary validation studies
utilizing immunofluorescence to identify CTCs, followed
by DNA FISH may confirm the incidence of specific
genomic aberrations in patient CTCs, for which the Epic
Platform is suitable.
4. Discussion
This study encompasses the analytical validation of the
Epic CTC detection platform where we assessed critical
assay performance characteristics including assay accura‐
cy, linearity, specificity and precision/repeatability (intra-
assay, inter-assay, intra-operator and inter-operator).
Notably, the platform demonstrated a high percentage of
nucleated cell recovery for all CLC concentrations tested
(Figure 3B), and showed excellent assay linearity (r2 = 0.999)
(Figure 3C). Furthermore, the assay is highly repeatable for
detecting CLCs at multiple dilutions within and across
assay runs and multiple operators (Figure 3D). The assay
is also highly specific, in that zero CTCs were detected in
unspiked healthy donor samples (Figure 3C, Figure 4).
While in-depth clinical feasibility studies are underway,
data from a small cohort of clinically confirmed all-comer
mCRPC patient samples tested with the Epic CTC Platform
showed that ≥1 traditional CTC/mL was detected in 89 %
of patient samples, whereas 100 % of samples had ≥1 CTC/
mL when additionally considering the CK(-) and apoptotic
CTC subpopulations. In this patient cohort, we observed
the presence of multiple CTC subtypes, including CK(+)
CTCs, CTC clusters, CK(-) CTCs and apoptotic CTCs. This
is in contrast to the healthy donor samples tested, in which
zero CTCs were enumerated in all 18 samples. In Figure 5,
we discuss the downstream capabilities of the Epic Plat‐
form, including methods to evaluate protein (immuno‐
fluorescence) and genetic (FISH, NGS) biomarkers.
In the last 10 years, great strides have been made with the
technological development of CTC detection strategies, as
well as advancements in the understanding of CTC
biology, resulting in over 16,000 publications. However,
further investigation of CTC utility in directing personal‐
ized medicine is warranted, and many studies and trials are
now underway to address this. Low CTC abundance poses
a challenge with respect to having a statistically significant
number of cells for biomarker analyses, and thus to the
evaluation of tumour heterogeneity. Low CTC incidence
has been reported for non-metastatic or locally advanced
prostate [32, 54] or locally advanced pancreatic adenocar‐
cinoma [55], and non-metastatic colorectal cancer [56],
which may limit the utility of CTC assays for diagnosis of
early stage disease. Increasing the sensitivity of CTC
detection may address this issue; however, increased
sensitivity may result in the detection of false-positive
results in healthy controls or in patients with benign disease
[57]. Additionally, some cancer indications such as ovarian
[58] and NSCLC [59] have reportedly low CTC numbers;
however, the low abundance of CTCs identified may be a
result of the CTC detection platform selected and reliance
on using CTC enrichment strategies. Emerging data show
that CTCs are detected in larger numbers in these indica‐
tions when using epithelial marker-independent ap‐
proaches [60-62].
Detection of CTCs with an epithelial-to-mesenchymal
transition (EMT) phenotype remains a challenge, and their
functional and clinical relevance are still under investiga‐
tion. CTC platforms that rely on epithelial marker enrich‐
ment are ill-suited to detect these cells [20]; however, there
is no universal biomarker that ensures the detection of
mesenchymal CTCs. For example, some EMT markers (i.e.,
vimentin) are expressed on the surrounding leukocytes,
and CTCs show a broad range of phenotypes during EMT
and may express neither cytokeratins nor EMT markers [4].
In addition to identifying additional mesenchymal mark‐
ers, it is unclear as to whether mesenchymal CTCs are even
capable of seeding distal metastases, as these cells may be
unable to undergo the reverse “mesenchymal-to-epithe‐
lial” transition [63]. CTCs may have an intermediate
phenotype where they partially downregulate epithelial
markers while partially upregulating mesenchymal
markers, or express neither. These highly plastic cells
suggest their stemness [64] but additional studies are
warranted to evaluate their clinical significance.
The Epic CTC Platform uses an unbiased CTC detection
approach in which additional CTC subpopulations includ‐
ing CTC clusters, CK(-) CTCs, small CTCs and apoptotic
CTCs are enumerated. While the biological significance of
each CTC subtype is still under investigation, emerging
literature suggests that each subtype may play an impor‐
tant role in tumour metastasis, epithelial-to-mesenchymal
transition (EMT), and as potential markers for cancer
therapeutic responses. Although not extensively validated
as a biomarker, the presence of CTC clusters is reported to
be a negative prognostic factor for survival in cohorts of
small-cell lung cancer [65], as well as breast cancer and
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prostate cancer patients [66]. Preclinical models suggest
that CTC clusters might have survival advantages in blood
circulation including resistance to programmed cell death
and physical sheer forces [65-68]. There is limited publish‐
ed data on the biological relevance of CK(-) CTCs; however,
it has been shown that CTCs of epithelial origin can display
a range of both epithelial and non-epithelial gene biomark‐
er signatures [4, 32, 69, 70]. Similarly, in-depth literature
describing the biological significance of apoptotic CTCs is
limited, although the enumeration of apoptotic CTCs has
been explored as a potential drug response biomarker [71].
Characterization of the prevalence and functional signifi‐
cance of these CTC subtypes as clinical markers for
predicting sensitivity to targeted therapies and under‐
standing disease progression is of great interest, and is
currently the subject of multiple ongoing clinical studies at
Epic Sciences.
An important feature of the Epic Platform is the capacity
for the creation of a biorepository of patient slides, which
may be frozen and stored for retrospective biomarker
analyses. While one CTC test uses two slides, approximate‐
ly 10-12 slides are created per patient sample and the
remaining slides are banked at -80 °C. In the wake of new
biomarker discoveries and/or generation of biomarker
hypotheses for a particular indication, banked patient
slides may be evaluated retrospectively and correlated
with clinical outcome data. So far, we have established
patient slide stability for storage at -80 °C for up to one year
with respect to their ability to retain CTCs and biomarker
expression. Longer-term stability studies of frozen patient
slides are currently underway.
While advancements in genomics and proteomics have
contributed to our molecular understanding of cancer,
emerging research also highlights inter-patient [72] as well
as spatial [73-77] and temporal [8-11] intra-patient hetero‐
geneity, both of which limit the efficacy of targeted
therapies and thus compromise patient outcomes. Charac‐
terizing intra-patient heterogeneity has been posited as a
means to intelligently guide precision-targeted therapies
based on the current state of disease [7, 78, 79] and the
development of resistance mechanisms to therapy. A
comprehensive approach based on the detection of a panel
of protein and genetic CTC biomarkers can give rise to a
patient tumour’s molecular signature, which will not only
inform the development of targeted therapeutic strategies,
but will also allow for patient surveillance based upon
molecular alterations over time. Evaluation of biomarker
panels in a liquid biopsy may provide the molecular
landscape of primary and metastatic lesions, while offering
the opportunity to evaluate molecular tumour evolution as
a real-time film instead of a single frame snapshot.
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